Pictet Asset Management Holding SA increased its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 11.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 206,580 shares of the company’s stock after purchasing an additional 20,777 shares during the quarter. Pictet Asset Management Holding SA owned 0.08% of BioNTech worth $20,363,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of BNTX. Headlands Technologies LLC purchased a new position in shares of BioNTech in the second quarter valued at $2,520,000. Bank of America Corp DE boosted its position in shares of BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after buying an additional 166,432 shares in the last quarter. Amundi boosted its position in shares of BioNTech by 24.5% in the 1st quarter. Amundi now owns 129,513 shares of the company’s stock worth $11,511,000 after buying an additional 25,506 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in BioNTech by 79.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock valued at $74,774,000 after acquiring an additional 337,412 shares during the last quarter. Finally, Flossbach Von Storch SE acquired a new stake in BioNTech in the 2nd quarter valued at about $207,142,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several research firms have weighed in on BNTX. Citigroup dropped their target price on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $128.00 to $105.00 in a research note on Tuesday, September 8th. HC Wainwright cut their price objective on BioNTech from $130.00 to $110.00 and set a “buy” rating for the company in a research report on Monday. UBS Group reduced their target price on BioNTech from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Wednesday, November 4th. Finally, Argus began coverage on BioNTech in a report on Thursday, October 8th. They set a “hold” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.27.
Get Our Latest Report on BioNTech
BioNTech Price Performance
NASDAQ:BNTX opened at $87.65 on Thursday. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The firm has a market cap of $22.17 billion, a price-to-earnings ratio of -12.80 and a beta of 1.28. The company’s 50-day moving average is $93.80 and its two-hundred day moving average is $96.25. The company has a current ratio of 8.55, a quick ratio of 8.52 and a debt-to-equity ratio of 0.01.
Insider Activity
In related news, CEO Ugur Sahin sold 72,000 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00. Following the transaction, the chief executive officer owned 108,209 shares of the company’s stock, valued at approximately $10,521,161.07. This represents a 39.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 807,209 shares of company stock worth $79,246,837 over the last quarter. Corporate insiders own 19.20% of the company’s stock.
BioNTech Company Profile
BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.
Featured Articles
- Five stocks we like better than BioNTech
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report).
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
